QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (157) Citing Articles via Google Scholar Google Scholar Articles by Paradis, E. Articles by LeBlanc, A. Search for Related Content PubMed PubMed Citation Articles by Paradis, E. Articles by LeBlanc, A. Pubmed/NCBI databases Medline Plus Health Information Alzheimer's Disease

 Previous Article  |  Next Article 

Volume 16, Number 23, Issue of December 1, 1996 pp. 7533-7539
Copyright ©1996 Society for Neuroscience

Amyloid  Peptide of Alzheimer's Disease Downregulates Bcl-2 and Upregulates Bax Expression in Human Neurons

Eric Paradis¹, Hélène Douillard¹, Maria Koutroumanis¹, Cynthia Goodyer², and Andréa LeBlanc^{1, 3}

¹ The Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, The Mortimer B. Davis Jewish General Hospital, Montréal, Québec, Canada, and the Departments of ² Pediatrics and ³ Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada

ABSTRACT

INTRODUCTION

MATERIALS AND METHODS

RESULTS

DISCUSSION

FOOTNOTES

REFERENCES

---

ABSTRACT

Neuronal apoptosis is a suspected cause of neurodegeneration in Alzheimer's disease (AD). Increased levels of amyloid  peptide (A) induce neuronal apoptosis in vitro and in vivo. The underlying molecular mechanism of A neurotoxicity is not clear. The normal concentration of A in cerebrospinal fluid is 4 nM. We treated human neuron primary cultures with 100 nM amyloid  peptides A_1-40 and A_1-42 and the control reverse peptide A_40-1. We find that although little neuronal apoptosis is induced by either peptide after 3 d of treatment, A_1-42 provokes a rapid and sustained downregulation of a key anti-apoptotic protein, bcl-2, whereas it increases levels of bax, a protein known to promote cell death. In contrast, the A_1-40 downregulation of bcl-2 is gradual, although the levels are equivalent to those of A_1-42-treated neurons by 72 hr of treatment. A_1-40 does not upregulate bax levels. The control, reverse peptide A_40-1, does not affect either bcl-2 or bax protein levels. In addition, we found that the A_1-40- and A_1-42- but not A_40-1-treated neurons had increased vulnerability to low levels of oxidative stress. Therefore, we propose that although high physiological amounts of A are not sufficient to induce apoptosis, A depletes the neurons of one of its anti-apoptotic mechanisms. We hypothesize that increased A in individuals renders the neurons vulnerable to age-dependent stress and neurodegeneration.

Key words: amyloid  peptide; human neuron primary cultures; bcl-2; bax; apoptosis; Alzheimer's disease

---

INTRODUCTION

Genetic, molecular, and cell biology evidence support a role for the amyloid  peptide (A) of 40 and 42 amino acids (A_1-40 and A_1-42) in the pathogenesis of Alzheimer's disease (AD): (1) Mutations of the amyloid precursor protein (APP), which is normally processed into A and a number of stable fragments, increase the production of A_1-40 or A_1-42 (Citron et al., 1992, 1994; Cai et al., 1993; Haass et al., 1994; Suzuki et al., 1994); (2) mutations of presenilin I and II genes of familial AD increase APP mRNA and A levels (Levy-Lahad et al., 1995; Querfurt et al., 1995; Sherrington et al., 1995; Sheuner et al., 1996); (3) the ratio of A_1-42 to A_1-40 increases in sporadic AD brains (Iwatsubo et al., 1994; Kuo et al., 1996); (4) Down's syndrome individuals who carry three copies of the APP gene and consequently overexpress APP mRNA and produce excess A invariably develop AD pathology (Wisniewski et al., 1985; Tanzi et al., 1987; Teller et al., 1996); and (5) transgenic mice overexpressing normal APP, mutant APP₇₁₇, or A develop features of AD pathology (Games et al., 1995; Higgins et al., 1995; Hsiao et al., 1995; LaFerla et al., 1995).

As cause rat hippocampal and cortical neuronal death in vitro (concentrations of 1-100 µM) and in vivo (Yankner et al., 1990; LaFerla et al., 1995). Treatment of cultured neurons with 25-100 µM A induces typical features of apoptosis: neurite beading, membrane blebbing, condensed chromatin, and DNA fragmentation (Forloni et al., 1993; Loo et al., 1993; Watt et al., 1994). Evidence of neuronal apoptosis is also observed in sporadic and familial AD brains (Anderson et al., 1994, 1996; Su et al., 1994; Satou et al., 1995; Yamatsuji et al., 1996). The mechanism by which A induces cell death or apoptosis is not yet clearly defined. A alters calcium levels, thereby promoting susceptibility to excitotoxic damage (Mattson et al., 1992), promotes free radical formation (Behl et al., 1994; Shearman et al., 1994), and possibly competes for nerve growth factor low-affinity receptor (Rabizadeh et al., 1994). In glial cells, A induces the production of cytokines, tumor necrosis factor, and reactive nitrogen intermediates, any of which can mediate neuronal cell death (Meda et al., 1995). Furthermore, A induces hyperphosphorylation of tau, which may promote neurofibrillary tangle formation and neurodegeneration (Busciglio et al., 1995).

In the present study, we analyzed the effect of 100 nM A_1-40 and A_1-42 and control reverse peptide A_40-1 on human primary neuron cultures. We measured cell death by various techniques and examined the effect of A on neuronal "death" bax and "anti-death" bcl-2 proteins. We do not detect significant cell death with A_1-40, A_1-42, or A_40-1, although there is a slight increase in terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) after 72 hr of treatment with A_1-40 and A_1-42 compared with A_40-1. Interestingly, A_1-40 and A_1-42 but not A_40-1 downregulate bcl-2. Furthermore, A_1-42 upregulates bax. In addition, the A-treated neurons show increased vulnerability to low levels of oxidative stress. We hypothesize that A jeopardizes the natural bcl-2-related protective mechanism in neurons and that this effect may lead to increased neuronal degeneration during age-dependent stresses such as oxidative stress, decreased energy metabolism, or decreasing growth factor levels.

---

MATERIALS AND METHODS

Neuron cultures. Human primary neurons were prepared as described (LeBlanc, 1995) from fetal brains of 13-17 weeks (Munsick, 1984). The brains were collected from human fetuses at the time of the therapeutic abortion in accordance with the Quebec Health Code (received Institutional Review Board approval). Briefly, the cerebrum is dissociated in trypsin (Life Technologies, Ontario) and deoxyribonuclease I (Boehringer Mannheim, Quebec), filtered through 40 and 130 µm nylon mesh, and plated at 3 × 10⁶ cells/ml of high-glucose-containing MEM supplemented with Earle's salts, 1 mM sodium pyruvate, 2 mM glutamine (all from Life Technologies), and 5% decomplemented serum (Hyclone, Logan, UT); 1 mM anti-mitotic fluorodeoxyuridine (Sigma, St. Louis, MO) is added to inhibit proliferation of contaminating astrocytes or other dividing cells. Under these conditions, neurons establish healthy neurite networks within 3 d and can be maintained for at least 4 weeks without showing signs of degeneration. Experiments were carried out on neurons 10 d after plating. The neuronal cultures typically contain >90% neurons.

Treatment of neurons with A. Fibrillar A_1-40, A_1-42 (Bachem Bioscience, Torrance, CA), and control reverse peptide A_40-1 (Sigma) were prepared by incubating freshly solubilized peptides at 25 µM in sterile distilled water at 37°C for 5 d (Pike et al., 1993). At the beginning of each experiment, A peptides were diluted to 100 nM in complete media. Neurons were treated for 6, 12, 24, 48, and 72 hr. For the 3 d incubation, the neuron media was changed after 48 hr.

Western blot analysis of bcl-2 and bax. After A peptide treatment on 3 × 10⁶ cells, neurons were washed in PBS and collected in 300 µl NP-40 lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP40, 5 mM EDTA, pH 8.0) containing 0.05% phenylmethylsulfonyl fluoride, 0.1 µg/ml pepstatin A, 1 µg/ml N-p-tosyl-L-lysine chloromethyl ketone, and 0.5 µg/ml leupeptin as protease inhibitors (all protease inhibitors from ICN, Montreal). Seventeen microliters of the lysate were submitted to electrophoresis on a 10% SDS-polyacrylamide gel and Western blot analysis with monoclonal anti-human bcl-2, sc-509 (Santa Cruz Biotech, Santa Cruz, CA), polyclonal anti-human bax, sc-493 (Santa Cruz Biotech), or monoclonal anti-human actin (kind gift from Dr. Eugenia Wang, Lady Davis Institute and McGill University). Immunoreactivity was detected using secondary anti-mouse (for bcl-2 and actin) or rabbit (for bax) antibodies conjugated to alkaline phosphatase (Jackson ImmunoResearch Laboratories, West Grove, PA) and substrates nitroblue tetrazolium and 5-bromo-chloro-3-indoyl-phosphate (Fisher, Montreal). The resulting Western blots were scanned on a Molecular Dynamics phosphorimager densitometric scanner. The data (pixels) were expressed as standard units, where 1 unit = bcl-2 or bax levels in 0 hr untreated neuron cultures. Statistical significance was determined by a two-tailed unpaired t test of A_1-40 or A_1-42 values compared with those of A_40-1.

MTT and lactate dehydrogenase (LDH) assays. Analysis of released LDH was performed by ELISA using the Cytotoxic 96 kit according to the manufacturer's instructions (Pharmacia Biotech, Quebec). The MTT reduction assay was carried out using the Cell Proliferation Kit I (Boehringer Mannheim). The MTT assay measures both cell death and proliferation and is based on the conversion of the yellow tetrazolium salt MTT to blue formazan by metabolically active cells. The resulting blue color was measured at absorbance 660nm and 550 nm. MTT reduction was calculated as Abs_660nm  Abs_550nm, and results are expressed as a percentage of the control untreated sample. Increased absorbance readings with time indicate proliferation, whereas decreased absorbance indicates cell death.

Determination of apoptosis in cells. Neurons were fixed in fresh 4% paraformaldehyde for 20 min and permeabilized in 0.1% Triton X-100, 0.1% sodium citrate. Cells were stained with 0.1 µg/ml propidium iodide (Sigma) for 20 min, rinsed in PBS, and mounted. TUNEL was performed using the in situ cell death detection kit AP as described by the manufacturer (Boehringer Mannheim, Quebec). DNA ladder was performed on 3 × 10⁶ cells. The cells were washed and harvested in PBS. After centrifugation, the cell pellet was incubated in 50 µl of a proteinase K/sarkosyl solution (50 mM Tris, pH 8.0, 10 mM EDTA, 0.5 mg/ml proteinase K, and 0.5% sarkosyl) for 2 hr at 50°C; 2.5 µl of RNaseA at 10 mg/ml was added, and the incubation continued for 2 hr at 50°C. The DNA was loaded on a 1.2% agarose gel in 1 × TBE and run at 50 V overnight.

Oxidative stress on neurons preexposed to A. Neurons were treated for 48 hr with A_1-40, A_1-42, and A_40-1 as described above. The media was replaced with 0, 0.1, and 1.0 µM H₂O₂ and incubated for another 48 hr. Cells were fixed and processed for TUNEL as described above. Because the number of apoptotic cells was very high in H₂O₂-treated neurons, five specific areas of each coverslip were counted and added as number of TUNEL-positive cells. The density of neurons required for survival in culture does not allow determination of exact cell numbers in this experiment. Therefore the results are expressed as total number of TUNEL-positive cells rather than percentage.

---

RESULTS

Neuronal degeneration in A-treated neurons

To study the effect of the A peptides, 10-d-old human primary neurons with elaborate neurite networks were treated with 100 nM fibrillar A_1-40 and A_1-42 for 6, 12, 18, 24, 48, and 72 hr. A_1-40 at 100 nM is ~25 × that of physiological A concentrations in cerebrospinal fluid (CSF) (Nakamura et al., 1994; Van Gool et al., 1994). Physiological concentrations of A_1-42 are not known. Our neuron cultures produce ~1/10 A_1-42 compared with A_1-40 (A. LeBlanc and S. Younkin, unpublished results). Therefore, 100 nM A_1-42 likely represents 250 × the physiological concentration in CSF. Phase-contrast micrography of acid/alcohol-fixed neurons shows that neurons do not undergo neurodegeneration in an acute manner with either A_1-40 or A_1-42 (Fig. 1). At 72 hr of treatment, neurites are thickened and beaded compared with control A_40-1-treated cells, but neither the cell density nor the neuronal bodies seem to be affected. The neuritic alterations in A-treated human fetal neurons is variable with each culture, suggesting that the heterogeneity of the sample population results in different degrees of susceptibility to A peptides. In time, however, each neuron culture treated with either A_1-40 or A_1-42 undergoes neurite beading by 72 hr of treatment.

---

Fig. 1. Neurite degeneration is observed after 72 hr of treatment with A peptides. Phase-contrast micrograph of primary neuron cultures treated with 100 nM A_1-40 or A_1-42 and control reverse peptide A_40-1 for 6, 12, and 72 hr. Arrows show neuritic beading, and arrowheads show neurite thickening.
[View Larger Version of this Image (208K GIF file)]

---

Studies of cell death in human primary neurons treated with A_1-40, A_1-42, and A_40-1

Cell death in culture is generally measured by the reduction of MTT activity and the release of LDH into the media. MTT is a tetrazolium salt cleaved to formazan by the mitochondrial respiratory chain enzyme succinate-tetrazolium reductase, which is active only in live cells. LDH is released into the cell media when cells die by necrosis. Although slightly decreasing MTT levels and increasing LDH activity with time indicate a certain amount of cell death in our cultures, there is no significant difference between A_1-40-, A_1-42-, and A_40-1-treated neurons (Fig. 2A,B). To determine whether apoptotic cell death occurred in the neuronal cultures, we looked for fragmented DNA by TUNEL staining, condensed chromatin by propidium iodide staining, and DNA ladder formation as a function of time of treatment. Although few condensed chromatin-containing neurons were observed by propidium iodide staining of three independent experiments (results not shown), ~2% of the neurons treated with A_1-40 and A_1-42 for 72 hr were TUNEL-positive against a background of 0.5% in A_40-1-treated neurons (Fig. 2C). The absence of DNA ladder formation confirmed the low level of apoptotic neurons in the A-treated cultures (not shown). These results were reproduced in three independent experiments.

---

Fig. 2. A peptides do not cause high levels of cell death in neuron primary cultures. Determination of cell death in A_1-40-, A_1-42-, and A_40-1-treated human primary neurons for 12, 24, 48, and 72 hr by MTT reduction assay expressed as a percentage of time 0 (n = 3 ± SEM) (A), LDH release assay (n = 3 ± SEM) (B), and TUNEL-positive cells in a representative experiment (C).
[View Larger Version of this Image (21K GIF file)]

---

A downregulates bcl-2 and upregulates bax

Bcl-2 and bax levels were assessed by Western blots to determine whether these key regulators of apoptosis were involved in the A-induced neurotoxic mechanism (Fig. 3). Using a monoclonal anti-human bcl-2 antibody and a polyclonal antisera to bax, we consistently saw decreased bcl-2 protein levels in A_1-40- and A_1-42-treated neurons compared with A_40-1 control cells (Fig. 3A). With A_1-42, we also observed increased bax protein levels. The equivalent levels of actin detected from each time point attest to the equal protein loading in each well of the gel. We quantitated the decreased bcl-2 and increased bax protein levels by densitometric scanning with a phosphorimager. We find that the bcl-2 protein level normalized to untreated cultures (0 hr) is rapidly reduced by >50% in A_1-42-treated neurons compared with A_40-1-treated cells (Fig. 3B). The effect is observed within 6 hr of treatment and sustained for up to 72 hr. A_1-40 also downregulates bcl-2 protein levels, but the effect is gradual, and a significant difference with the control A_40-1 reverse peptide is observed only at 72 hr.

---

Fig. 3. A peptides downregulate bcl-2 protein and upregulate bax protein levels in primary neuron cultures. A, Western blot analysis of one representative experiment of bcl-2, bax, and actin protein levels in neurons treated with A_1-40, A_1-42, and A_40-1 for 0, 6, 12, 24, 48, and 72 hr. B, Densitometric quantitation by phosphorimager of bcl-2 protein levels in neuron cultures normalized to levels in 0 hr culture (mean of three independent experiments, ± SEM) shows rapidly decreasing bcl-2 protein levels in A_1-42 (p < 0.01, from 6-72 hr) and a gradual decrease in A_1-40-treated neurons (p < 0.01, at 72 hr only) compared with A_40-1-treated neurons. C, Densitometric quantitation by phosphorimager of bax protein levels in neuron cultures normalized to levels in untreated (0 hr) sister culture (mean of three independent experiments, ± SEM) shows rapidly increasing bax protein levels in A_1-42 (p < 0.05, between 24-72 hr) but no difference in A_1-40- compared with A_40-1-treated neurons.
[View Larger Version of this Image (50K GIF file)]

---

In contrast to bcl-2 protein levels, bax protein increases three- to fourfold in A_1-42-treated neurons compared with A_40-1 (Fig. 3C). The increase in bax is apparent at 6 hr and peaks at 24 hr. The A_1-40 has no effect on bax levels in neurons.

The results indicate that a 25-fold increase in the level of A_1-40 and a 250-fold increase in A_1-42 are not sufficient to induce significant apoptosis, although some cells in the neuronal culture are clearly more vulnerable than others to the peptides. Downregulation of bcl-2 and upregulation of bax in these A-treated neurons demonstrate that the peptides have an effect on proteins that mediate apoptosis. To determine whether the neurons exposed to A were more vulnerable to an age-dependent secondary insult such as oxidative stress, we first treated the neurons with A_1-40 and A_1-42 for 48 hr and then exposed them to low oxidative stress levels, using 0.1 and 1.0 µM H₂O₂. The A_1-40- and A_1-42-treated cultures contain 10-20 times more TUNEL-positive cells when treated with 0.1 and 1.0 µM H₂O₂, whereas these low levels of H₂O₂ do not increase apoptosis in A_40-1-treated neurons (Fig. 4). These levels of oxidative stress also had no effect on untreated neurons that showed results equivalent to those of the control A_40-1 (not shown).

---

Fig. 4. Susceptibility to H₂O₂ in neurons pretreated with A_1-40 and A_1-42 but not A_40-1. TUNEL labeling detects increased apoptosis in neurons pretreated for 48 hr with A_1-40 and A_1-42 and then submitted to 0.1 µM H₂O₂ and 1.0 µM H₂O₂ for 48 hr. In contrast, sister cultures treated with the control peptide A_40-1 do not show increased sensitivity to low levels of oxidative stress. Data represent an average of four experiments.
[View Larger Version of this Image (45K GIF file)]

---

---

DISCUSSION

We find that elevated but physiological concentrations of A_1-40 and A_1-42 are insufficient to initiate significant human neuronal apoptosis in cultures. Nanomolar concentrations of fresh or aged A that are likely to be physiological concentrations do not show neurotoxic effects in most systems, and human neurons have previously been shown to be resistant to micromolar concentrations of A (Mattson et al., 1992; Shearman et al., 1994). Yet, there is considerable evidence that A plays a primary role in Alzheimer's disease. We find that 100 nM A_1-42 rapidly decreases bcl-2 protein levels in neurons, whereas it increases bax levels. Interestingly, bcl-2 protein levels are also decreased in 100 nM A_1-40-treated neurons, but only gradually, and reach A_1-42-treated levels by 72 hr, whereas bax levels remain unaffected. In addition, neurons preexposed to either A_1-40 or A_1-42 show increased sensitivity to a mild oxidative stress. Therefore, we propose a novel hypothesis that in Alzheimer's disease, neuronal degeneration may be caused by A-mediated downregulation of bcl-2 rendering the neurons vulnerable to age-dependent secondary insults such as oxidative stress, decreasing levels of growth factors, or diminished glucose metabolism (Coyle and Puttfarcken, 1993).

A neurotoxicity has been widely investigated in a number of neuronal systems with the use of very high concentrations of the aggregated or fibrillar peptide (1-100 µM). The underlying mechanisms mediating A neurotoxicity are attributed to either oxidative stress (Behl et al., 1994; Thomas et al., 1996) or the destabilization of intracellular calcium levels (Mattson et al., 1992). Our observations are consistent with both mechanisms. Bcl-2 is well established as an anti-death protein in neurons. Bcl-2 can avert survival factor deprivation-induced neuronal apoptosis in sympathetic cervical ganglia, in sensory primary neurons, and in continuous cell lines such as PC12 cells (Garcia et al., 1992; Batistatou et al., 1993; Mah et al., 1993; Martinou et al., 1994). Bcl-2 and another neuronal bcl-2-related anti-death protein, bcl-xL, also prevent hypoxia and axotomy-induced neuronal death in vivo (Dubois-Dauphin et al., 1994; Jacobson and Raff, 1995; Shimizu et al., 1995). Therefore, bcl-2 and related anti-death proteins are key regulators of programmed cell death in neurons. Any disruption in the level of these proteins is likely to result in increased neuronal vulnerability. The exact mechanism by which downregulation of bcl-2 enhances neuronal vulnerability to oxidative stress is not clear. Although it has been proposed by some that bcl-2 directly protects cells against reactive oxygen species (Hockenbery et al., 1993; Kane et al., 1993; Veis et al., 1993), others find that bcl-2 protects cells without decreasing reactive oxygen species (Jacobson and Raff, 1995; Shimizu et al., 1995). On the other hand, it has been shown that in human neurons A enhances excitotoxicity, and this effect is attributed to increased intracellular calcium (Mattson et al., 1992). Increased calcium levels are also linked to apoptosis, and it has been suggested that bcl-2 is involved in the maintenance of cellular calcium homeostasis (Bafy et al., 1993). Downregulation of bcl-2 in human neurons may explain the dysregulation of intracellular calcium levels by A. Our results show that the effect of A_1-42 on bcl-2 and bax levels is more drastic than that of A_1-40. These results are consistent with the higher aggregative potential of A_1-42 (Jarrett et al., 1993) and the aggregation-dependent neurotoxicity of A peptides (Pike et al., 1993).

On the basis of the low levels of neurotoxicity in our human primary cultures exposed to high physiological concentrations of A and the fact that familial AD is manifestly a disease of the aged, we propose that A by itself is unlikely to induce apoptosis in AD patients and that it requires a second age-dependent factor to be neurotoxic. Our data suggest the possibility that downregulation of bcl-2 in the presence of A renders the cell vulnerable to age-dependent stress. Although there is no overwhelming evidence for apoptotic neurons in AD brains, there are indications that such a mechanism can occur. Bcl-2 immunoreactivity generally is increased in AD neurons but decreased in degenerating neurons (Satou et al., 1995). Other evidence of apoptosis in AD brains includes increased apopTag and c-jun immunoreactivity, evidence of DNA fragmentation, and bcl-2-sensitive apoptosis induced by familial AD mutants of APP (Mullaart et al., 1990; Anderson et al., 1994; Su et al., 1994; Lassmann et al., 1995; Anderson et al., 1996; Yamatsuji et al., 1996). The effect of A on fetal neurons may be criticized as a model for AD, an aging disease. The fact remains that these are the only source of human neurons at this time. The decreased bcl-2 expression observed in degenerating neurons of AD brains (Satou et al., 1995) supports the possibility that the effect of A on bcl-2 levels in fetal neuron cultures is reproduced in vivo in the brain of adult individuals.

In summary, our data show that although 25-fold A_1-40 and 250-fold A_1-42 concentrations do not cause extensive apoptosis in human neurons, A does alter the anti-apoptotic protective balance by downregulating bcl-2 and upregulating bax protein levels, and it increases the vulnerability of these cells to oxidative stress. The data support the hypothesis that increased A concentrations in AD CSF render the neurons vulnerable to age-dependent stresses such as oxidative stress.

---

FOOTNOTES

Received July 30, 1996; revised Sept. 17, 1996; accepted Sept. 18, 1996.

  

This work was supported by the Alzheimer Society of Canada, National Institutes of Health National Institute of Neurological Disorders and Stroke Grant RO1 NS31700, and the Fond de Recherche en Santé du Québec (A.L.) and Medical Research Council (C.G.).

Correspondence should be addressed to Andréa LeBlanc, Lady Davis Institute, 3755 Ch. Côte Ste-Catherine, Montréal, Québec, Canada H3T 1E2.

---

REFERENCES

• Anderson AJ, Cummings BJ, Cotman CW (1994) Increased immunoreactivity of jun- and fos-related proteins in Alzheimer's disease: association with pathology. Exp Neurol 125:286-295 . [ISI][Medline]
• Anderson AJ, Su JH, Cotman CW (1996) DNA damage and apoptosis in Alzheimer's disease: colocalization with c-jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 16:1710-1719 . [Abstract/Free Full Text]
• Bafy G, Miyashita J, Williamson J, Reed J (1993) Apoptosis induced by withdrawal of interleukin-3 (IL-3)-dependent hemapoeitic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 268:6511-6519. [Abstract/Free Full Text]
• Batistatou A, Merry DE, Korsmeyer SJ, Greene LA (1993) Bcl-2 affects survival but not neuronal differentiation of PC12 cells. J Neurosci 13:4422-4428 . [Abstract]
• Behl C, Davis J, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid  protein toxicity. Cell 77:817-827 . [ISI][Medline]
• Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) -amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14:879-888 . [ISI][Medline]
• Cai X, Golde T, Younkin S (1993) Release of excess amyloid  protein from a mutant amyloid  protein precursor. Science 259:514-516 . [Abstract/Free Full Text]
• Citron M, Oltersdorf T, Haass C, McConlogue L, Hung A, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe D (1992) Mutation of the -amyloid precursor protein in familial Alzheimer's disease increases -amyloid protein production. Nature 360:672-679 . [Medline]
• Citron M, Vigo-Pelfrey C, Teplow D, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe D (1994) Excessive production of amyloid -protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91:11993-11997 . [Abstract/Free Full Text]
• Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695 . [Abstract/Free Full Text]
• Dubois-Dauphin M, Frankowski H, Tsujimoto Y, Huarte J (1994) Neonatal motorneuron overexpressing the bcl-2 protooncogene in transgenic mice are protected from axotomy-induced cell death. Proc Natl Acad Sci USA 91:3309-3313 . [Abstract/Free Full Text]
• Forloni G, Chiesa R, Smiroldo S, Verga L, Salmona M, Tagliavini F, Angeretti N (1993) Apoptosis mediated neurotoxicity induced by chronic application of  amyloid fragment 25-35. NeuroReport 4:523-526 . [ISI][Medline]
• Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F -amyloid protein. Nature 373:523-527 . [Medline]
• Garcia I, Martinou I, Tsujimoto Y, Martinou J (1992) Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 258:302-304 . [Abstract/Free Full Text]
• Haass C, Hung A, Selkoe D, Teplow D (1994) Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid -protein precursor. J Biol Chem 269:17741-17748 . [Abstract/Free Full Text]
• Higgins LS, Rodems JM, Catalano R, Cordell B (1995) Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for -APP751. Proc Natl Acad Sci USA 92:4402-4406 . [Abstract/Free Full Text]
• Hockenbery DM, Oltvai ZN, Yin X-M, Milliman C, Korsmeyer SJ (1993) Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251 . [ISI][Medline]
• Hsiao K, Borcheldt D, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, Iadecola C, Clark B, Carlson G (1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor protein. Neuron 15:1203-1208 . [ISI][Medline]
• Iwatsubo T, Okada A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A42(43) and A40 in senile plaques with end-specific A monoclonals: evidence that an initially deposited species is A42(43). Neuron 13:45-53 . [ISI][Medline]
• Jacobson MD, Raff M (1995) Programmed cell death and bcl-2 protection in very low oxygen. Nature 374:814-816 . [Medline]
• Jarrett J, Berger E, Lansbury P (1993) The carboxy terminus of the -amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697 . [Medline]
• Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla E, Valentine JS, Ord T, Bredesen DE (1993) Bcl-2 inhibition of neural cell death: decreased generation of reactive oxygen species. Science 262:1274-1277 . [Abstract/Free Full Text]
• Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble A (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081 . [Abstract/Free Full Text]
• LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G (1995) The Alzheimer's A peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nature Genet 9:21-30 . [ISI][Medline]
• Lassmann H, Bancher C, Breitschopf H, Wegiel J, Bobinski M, Jellinger K, Wisniewski H (1995) Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89:35-41 . [Medline]
• LeBlanc AC (1995) Increased production of 4 kDa amyloid  peptide in serum-deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci 15:7837-7846. [Abstract]
• Levy-Lahad E, Wasco W, Poorkej P, Romano DM, Oshima J, Pettingell WH, Yu C, Jondro P, Schmidt S, Wang K, Crowley A, Fu Y, Guenette S, Galas D, Nemens E, Wijsman E, Bird T, Schellenberg G, Tanzi R (1995) Candidate gene for the chromosome 1 familial Alzheimer's Disease locus. Science 269:973-977 . [Abstract/Free Full Text]
• Loo D, Copani A, Pike CJ, Whittemore E, Walencewicz AJ, Cotman CW (1993) Apoptosis is induced by -amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90:7951-7955 . [Abstract/Free Full Text]
• Mah SP, Zhong LT, Liu Y, Roghani A, Edwards RH, Bredesen DE (1993) The protooncogene bcl-2 inhibits apoptosis in PC12 cells. J Neurochem 60:1183-1186 . [ISI][Medline]
• Martinou J-C, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, Talabot D, Catsicas S, Pietra C, Huarte J (1994) Overexpression of bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 13:1017-1030 . [ISI][Medline]
• Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE (1992) -amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12:376-389 . [Abstract]
• Meda L, Cassatella M, Szendrei G, Otvos L, Baron P, Villalba M, Ferrari D, Rossi F (1995) Activation of microglial cells by -amyloid protein and interferon-gamma. Nature 374:647-650 . [Medline]
• Mullaart E, Boerrigter M, Ravid R, Swabb D, Vijg J (1990) Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11:169-173 . [ISI][Medline]
• Munsick RA (1984) Human foetal extremity lengths in the interval from 9 to 21 menstrual weeks of pregnancy. Am J Obstet Gynecol 149:883-887 . [ISI][Medline]
• Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung T, Shaffer L, Golde T, Younkin L, Younkin S, Hirai S (1994) Amyloid  protein levels in cerebrovascular fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 36:903-911 . [ISI][Medline]
• Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by -amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13:1676-1687 . [Abstract]
• Querfurt HW, Wisjsman EM, St. George Hyslop P, Selkoe D (1995) APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer's disease-1 family. Mol Brain Res 28:319-337. [Medline]
• Rabizadeh A, Bitler CM, Butcher LL, Bredesen DE (1994) Expression of the low-affinity nerve growth factor receptor enhances -amyloid peptide toxicity. Proc Natl Acad Sci USA 91:10703-10706. [Abstract/Free Full Text]
• Satou T, Cummings BJ, Cotman CW (1995) Immunoreactivity for bcl-2 protein within neurons in the Alzheimer's disease brain increases with disease severity. Brain Res 697:35-43 . [ISI][Medline]
• Shearman M, Ragan C, Iversen L (1994) Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of -amyloid-mediated cell death. Proc Natl Acad Sci USA 91:1470-1474 . [Abstract/Free Full Text]
• Sherrington R, Rogaev EJ, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tauda T, Mar L, Foncin J-F, Bruni AC, Montreal MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Pollinsky RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser P, Rommens JM, St. George-Hyslop PH (1995) Cloning of a gene bearing mis-sense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760 . [Medline]
• Sheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2:864-870. [ISI][Medline]
• Shimizu S, Eguchi Y, Kosaka H, Kamlike W, Matsuda H, Tsujimoto Y (1995) Prevention of hypoxia-induced cell death by bcl-2 and bcl-xL. Nature 374:811-813 . [Medline]
• Su J, Anderson A, Cummings B, Cotman C (1994) Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5:2529-2533 . [ISI][Medline]
• Suzuki N, Cheung T, Cai D, Odaka A, Laslo O, Eckman C, Golde T, Younkin S (1994) An increased percentage of long amyloid  protein secreted by familial amyloid  protein precursor (APP117) mutants. Science 264:1336-1340 . [Abstract/Free Full Text]
• Tanzi R, Gusella J, Watkins P, Bruns G, St. George-Hyslop P, Van Keuren M, Patterson D, Pagan S, Kurnit D, Neve R (1987) Amyloid  protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235:880-884 . [Abstract/Free Full Text]
• Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezinni P, Bertolini S, Mann DMA, Tabaton M, Gambetti P (1996) Presence of soluble -amyloid peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2:93-95 . [ISI][Medline]
• Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) -amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380:168-171 . [Medline]
• Van Gool WA, Schenk DB, Bolhuis PA (1994) Concentrations of amyloid- peptide in cerebrospinal fluid increase with age in patients free from neurodegenerative disease. Neurosci Lett 172:122-124 . [ISI][Medline]
• Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240 . [ISI][Medline]
• Watt JA, Pike CJ, Walencewicz AJ, Cotman CW (1994) Ultrastructural analysis of -amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res 661:147-156 . [ISI][Medline]
• Wisniewski K, Wisniewski H, Wen G (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17:278 . [ISI][Medline]
• Yamatsuji T, Okamoto T, Takeda S, Murayama Y, Tanaka N, Nishimoto I (1996) Expression of V642 APP mutant causes cellular apoptosis as Alzheimer trait-linked phenotype. EMBO J 15:498-509 . [ISI][Medline]
• Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid  protein: reversal by tachykinin neuropeptides. Science 250:279-286 . [Abstract/Free Full Text]

---

Copyright ©1996 Society for Neuroscience   0270-6474/1996/167533-07$05.00/0

This article has been cited by other articles:

				D. H. Kim and J. A. Frangos Effects of Amyloid {beta}-Peptides on the Lysis Tension of Lipid Bilayer Vesicles Containing Oxysterols Biophys. J., July 15, 2008; 95(2): 620 - 628. [Abstract] [Full Text] [PDF]

				V. Minicozzi, F. Stellato, M. Comai, M. D. Serra, C. Potrich, W. Meyer-Klaucke, and S. Morante Identifying the Minimal Copper- and Zinc-binding Site Sequence in Amyloid-{beta} Peptides J. Biol. Chem., April 18, 2008; 283(16): 10784 - 10792. [Abstract] [Full Text] [PDF]

				L. Wang, P. Chanvorachote, D. Toledo, C. Stehlik, R. R. Mercer, V. Castranova, and Y. Rojanasakul Peroxide Is a Key Mediator of Bcl-2 Down-Regulation and Apoptosis Induction by Cisplatin in Human Lung Cancer Cells Mol. Pharmacol., January 1, 2008; 73(1): 119 - 127. [Abstract] [Full Text] [PDF]

				P. Chanvorachote, U. Nimmannit, C. Stehlik, L. Wang, B.-H. Jiang, B. Ongpipatanakul, and Y. Rojanasakul Nitric Oxide Regulates Cell Sensitivity to Cisplatin-Induced Apoptosis through S-Nitrosylation and Inhibition of Bcl-2 Ubiquitination. Cancer Res., June 15, 2006; 66(12): 6353 - 6360. [Abstract] [Full Text] [PDF]

				M. Yao, T.-V. V. Nguyen, and C. J. Pike {beta}-Amyloid-Induced Neuronal Apoptosis Involves c-Jun N-Terminal Kinase-Dependent Downregulation of Bcl-w J. Neurosci., February 2, 2005; 25(5): 1149 - 1158. [Abstract] [Full Text] [PDF]

				L. F. Jarskog, E. S. Selinger, J. A. Lieberman, and J. H. Gilmore Apoptotic Proteins in the Temporal Cortex in Schizophrenia: High Bax/Bcl-2 Ratio Without Caspase-3 Activation Am J Psychiatry, January 1, 2004; 161(1): 109 - 115. [Abstract] [Full Text] [PDF]

				Y. Zhang, Y. Hong, Y. Bounhar, M. Blacker, X. Roucou, O. Tounekti, E. Vereker, W. J. Bowers, H. J. Federoff, C. G. Goodyer, et al. p75 Neurotrophin Receptor Protects Primary Cultures of Human Neurons against Extracellular Amyloid {beta} Peptide Cytotoxicity J. Neurosci., August 13, 2003; 23(19): 7385 - 7394. [Abstract] [Full Text] [PDF]

				A. M. Minogue, A. W. Schmid, M. P. Fogarty, A. C. Moore, V. A. Campbell, C. E. Herron, and M. A. Lynch Activation of the c-Jun N-terminal Kinase Signaling Cascade Mediates the Effect of Amyloid-{beta} on Long Term Potentiation and Cell Death in Hippocampus: A ROLE FOR INTERLEUKIN-1{beta}? J. Biol. Chem., July 18, 2003; 278(30): 27971 - 27980. [Abstract] [Full Text] [PDF]

				M. P. Mattson, S. L. Chan, and W. Duan Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior Physiol Rev, July 1, 2002; 82(3): 637 - 672. [Abstract] [Full Text] [PDF]

				I. I. Kruman, T. S. Kumaravel, A. Lohani, W. A. Pedersen, R. G. Cutler, Y. Kruman, N. Haughey, J. Lee, M. Evans, and M. P. Mattson Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer's Disease J. Neurosci., March 1, 2002; 22(5): 1752 - 1762. [Abstract] [Full Text] [PDF]

				Y. Zhang, R. McLaughlin, C. Goodyer, and A. LeBlanc Selective cytotoxicity of intracellular amyloid {beta} peptide1-42 through p53 and Bax in cultured primary human neurons J. Cell Biol., February 4, 2002; 156(3): 519 - 529. [Abstract] [Full Text] [PDF]

				C. N. O'Donovan, D. Tobin, and T. G. Cotter Prion Protein Fragment PrP-(106-126) Induces Apoptosis via Mitochondrial Disruption in Human Neuronal SH-SY5Y Cells J. Biol. Chem., November 16, 2001; 276(47): 43516 - 43523. [Abstract] [Full Text] [PDF]

				Y. Zhang, C. Goodyer, and A. LeBlanc Selective and Protracted Apoptosis in Human Primary Neurons Microinjected with Active Caspase-3, -6, -7, and -8 J. Neurosci., November 15, 2000; 20(22): 8384 - 8389. [Abstract] [Full Text] [PDF]

				K. Breitschopf, J. Haendeler, P. Malchow, A. M. Zeiher, and S. Dimmeler Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway Mol. Cell. Biol., March 1, 2000; 20(5): 1886 - 1896. [Abstract] [Full Text]

				B De Strooper and W Annaert Proteolytic processing and cell biological functions of the amyloid precursor protein J. Cell Sci., January 6, 2000; 113(11): 1857 - 1870. [Abstract] [PDF]